CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cipher Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cipher Pharmaceuticals Inc
5750 Explorer Drive,, Suite 404
Phone: (905) 602-5840p:905 602-5840 MISSISSAUGA, ON  L4W 0A9  Canada Ticker: DND DND
This company ceased filing statements with the SEC on 1/17/2017.
Business Summary
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Interim Chief Executive Officer Craig J.Mull 7/29/2019 3/26/2019
Chief Financial Officer BryanJacobs 8/15/2022 8/15/2022
Vice President - Scientific and Medical Affairs DianeGajewczyk 6/4/2018 6/4/2018
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
INNOCUTIS Holdings LLC 171 Church Street Charlestonn SC United States

Business Names
Business Name
Aggrastat®
Brinavess®
CPH
4 additional Business Names available in full report.

General Information
Number of Employees: 6 (As of 12/31/2022)
Outstanding Shares: 24,107,316 (As of 4/12/2024)
Stock Exchange: TSE
Fax Number: (905) 602-5840
Email Address: info@cipherpharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024